Technical Analysis for INSY - Insys Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 4.21 -2.09% -0.09
INSY closed down 2.09 percent on Thursday, April 18, 2019, on 64 percent of normal volume.

Earnings due: May 6

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical INSY trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
20 DMA Resistance Bearish -2.09%
180 Bearish Setup Bearish Swing Setup -2.09%
Bollinger Band Squeeze Range Contraction -2.09%
BB Squeeze + Lower Band Touch Range Contraction -2.09%
Outside Day Range Expansion -2.09%

Older signals for INSY ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
INSYS Therapeutics, Inc., a development stage company, develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company's cancer-supportive care and cancer therapy product candidates include Fentanyl sublingual spray, a single-use product for the treatment of breakthrough cancer pain; and Dronabinol SG capsule, an ANDA approved product and Dronabinol Oral Solution, which completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting, and appetite stimulation in AIDS patients. It also develops proprietary cancer therapeutics comprising LEP-ETU, a NeoLipid liposomal, which is in Phase II clinical development stage to enhance efficacy and reduce paclitaxel-related side effects. The company was founded in 2002 and is based in Phoenix, Arizona.
Medicine Cancer Pharmaceutical Chemical Compounds Organic Compounds Oncology Pharmaceutical Products Chemotherapy Cancer Treatments Antineoplastic Drugs Euphoriants Cancer Therapeutics Vomiting AIDS Cancer Therapy Paclitaxel Treating Cancer Chemotherapy Induced Nausea
Is INSY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 11.65
52 Week Low 3.35
Average Volume 921,846
200-Day Moving Average 6.4333
50-Day Moving Average 5.013
20-Day Moving Average 4.598
10-Day Moving Average 4.582
Average True Range 0.3352
ADX 19.84
+DI 15.866
-DI 31.0052
Chandelier Exit (Long, 3 ATRs ) 3.9644
Chandelier Exit (Short, 3 ATRs ) 5.0056
Upper Bollinger Band 4.9572
Lower Bollinger Band 4.2388
Percent B (%b) -0.04
BandWidth 15.624184
MACD Line -0.1443
MACD Signal Line -0.1131
MACD Histogram -0.0312
Fundamentals Value
Market Cap 306.05 Million
Num Shares 72.7 Million
EPS -0.22
Price-to-Earnings (P/E) Ratio -19.14
Price-to-Sales 2.18
Price-to-Book 1.57
PEG Ratio -0.62
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.57
Resistance 3 (R3) 4.59 4.48 4.51
Resistance 2 (R2) 4.48 4.39 4.48 4.49
Resistance 1 (R1) 4.35 4.34 4.30 4.33 4.47
Pivot Point 4.24 4.24 4.22 4.24 4.24
Support 1 (S1) 4.11 4.15 4.06 4.09 3.95
Support 2 (S2) 4.00 4.10 4.00 3.93
Support 3 (S3) 3.87 4.00 3.91
Support 4 (S4) 3.85